Executive VP & Chief Product Officer Resigns, Transitions to Advisor Role
NUS sits 24% above its 52-week low of $5.775.
Summary
Nu Skin's Executive Vice President and Chief Product Officer, Steven K. Hatchett, has resigned due to family health reasons but will remain as a strategic product advisor.
Key Events · Executive and Board Changes · NUS
-
Executive Resignation
Steven K. Hatchett resigned from his position as Executive Vice President and Chief Product Officer, effective May 8, 2026.
-
Reason for Departure
The resignation is attributed to family health circumstances.
-
Transition to Advisory Role
Mr. Hatchett will remain with the company as a strategic product advisor with an annual salary of $147,478.
-
Context of Recent Financials
This executive change follows recent reports of a 12% revenue decline and a significant drop in EPS for Q1 2026, as disclosed on May 7th and 8th.
Analysis · NUS · Trade & Services
This filing reports the resignation of Steven K. Hatchett, Executive Vice President and Chief Product Officer, effective May 8, 2026, due to family health circumstances. While the departure of a C-suite executive is generally a negative signal, his transition to a strategic product advisor role provides some continuity. This change occurs amidst recent negative financial results, including a 12% revenue decline and a sharp drop in EPS for Q1 2026, which may amplify investor scrutiny of leadership stability.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NUS was trading at $7.16 on NYSE in the Trade & Services sector, with a market capitalization of approximately $352.1M. The 52-week trading range was $5.78 to $14.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.